Avid Bioservices, Inc.

  • Market Cap: Micro Cap
  • Industry: Biotechnology
  • ISIN: US05368M1062
USD
12.49
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Avid Bioservices, Inc. stock-summary
stock-summary
Avid Bioservices, Inc.
Biotechnology
Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO). The Company is focused on development and Current Good Manufacturing Practices (CGMP) manufacturing of biopharmaceutical products derived from mammalian cell culture. The Company provides a range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The Company’s services include CGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The Company also provides process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization.
Company Coordinates stock-summary
Company Details
2642 Michelle Dr Ste 200 , TUSTIN CA : 92780-7019
stock-summary
Tel: 1 714 50861001 415 6757401
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 68 Schemes (50.15%)

Foreign Institutions

Held by 86 Foreign Institutions (8.54%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Joseph Carleone
Independent Non-Executive Chairman of the Board
Mr. Nicholas Green
President, Chief Executive Officer, Director
Mr. Richard Hancock
Director
Mr. Mark Bamforth
Independent Director
Dr. Catherine Mackey
Independent Director
Mr. Gregory Sargen
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
33 Million
(Quarterly Results - Oct 2024)
Net Profit:
-17 Million
stock-summary
Industry

Biotechnology

stock-summary
Market cap

USD 799 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

98.15%

stock-summary
Debt Equity

2.72

stock-summary
Return on Equity

-339.34%

stock-summary
Price to Book

17.83